Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection

被引：0

作者：

Glushko, Tetiana ^{[1
]}

Costello, James ^{[1
]}

Chima, Ranjit ^{[1
]}

McGettigan, Melissa ^{[1
]}

Kim, Richard ^{[1
]}

Jeong, Daniel ^{[1
]}

Qayyum, Aliya ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 2902 USF Magnolia Dr, Tampa, FL 33612 USA

来源：

EUROPEAN JOURNAL OF RADIOLOGY | 2025年 / 187卷

关键词：

BILIARY-TRACT CANCER; MUTATIONS; CHEMOTHERAPY; ARID1A; MULTICENTER; EXPRESSION; PROGNOSIS; SURVIVAL; FEATURES; PATHWAY;

D O I：

10.1016/j.ejrad.2025.112056

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Cholangiocarcinoma is a highly lethal disease with a 5-year overall survival rate of 7-20%. A minority of patients present with resectable disease, and relapse rates remain high. Emerging data from next generation sequencing analysis have identified various actionable mutations which drive the different disease courses opening door to precision medicine and targeted therapies. This review focuses on the clinical significance of genetic alterations as well as the role of systemic therapies, immunotherapy and targeted therapies for intrahepatic cholangiocarcinoma.

引用

页数：28

共 88 条

[1] Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].

Abou-Alfa, Ghassan K. ;

Macarulla, Teresa ;

Javle, Milind M. ;

Kelley, Robin K. ;

Lubner, Sam J. ;

Adeva, Jorge ;

Cleary, James M. ;

Catenacci, Daniel V. ;

Borad, Mitesh J. ;

Bridgewater, John ;

Harris, William P. ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Whisenant, Jonathan ;

Lowery, Maeve A. ;

Goyal, Lipika ;

Shroff, Rachna T. ;

El-Khoueiry, Anthony B. ;

Fan, Bin ;

Wu, Bin ;

Chamberlain, Christina X. ;

Jiang, Liewen ;

Gliser, Camelia ;

Pandya, Shuchi S. ;

Valle, Juan W. ;

Zhu, Andrew X. .

LANCET ONCOLOGY, 2020, 21 (06) :796-807

[2] Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer [J].

Amatu, A. ;

Sartore-Bianchi, A. ;

Bencardino, K. ;

Pizzutilo, E. G. ;

Tosi, F. ;

Siena, S. .

ANNALS OF ONCOLOGY, 2019, 30 :VIII5-VIII15

[3] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types [J].

Amatu, Alessio ;

Sartore-Bianchi, Andrea ;

Siena, Salvatore .

ESMO OPEN, 2016, 1 (02)

[4] BAP1 mutation-associated cholangiocarcinoma: An aggressive disease [J].

Anand, Deepa ;

Churi, Chaitanya ;

Rashid, Asif ;

Shroff, Rachna T. ;

Zuo, Mingxin ;

Conrad, Claudius ;

Vauthey, Jean-Nicolas ;

Javle, Milind M. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

[5] Spectrum of Findings Seen in Patients With IDH1/2-Mutant Cholangiocarcinoma [J].

不详 .

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2025, 33 (02) :417-425

[6] Cholangiocarcinoma 2020: the next horizon in mechanisms and management [J].

Banales, Jesus M. ;

Marin, Jose J. G. ;

Lamarca, Angela ;

Rodrigues, Pedro M. ;

Khan, Shahid A. ;

Roberts, Lewis R. ;

Cardinale, Vincenzo ;

Carpino, Guido ;

Andersen, Jesper B. ;

Braconi, Chiara ;

Calvisi, Diego F. ;

Perugorria, Maria J. ;

Fabris, Luca ;

Boulter, Luke ;

Macias, Rocio I. R. ;

Gaudio, Eugenio ;

Alvaro, Domenico ;

Gradilone, Sergio A. ;

Strazzabosco, Mario ;

Marzioni, Marco ;

Coulouarn, Cedric ;

Fouassier, Laura ;

Raggi, Chiara ;

Invernizzi, Pietro ;

Mertens, Joachim C. ;

Moncsek, Anja ;

Rizvi, Sumera ;

Heimbach, Julie ;

Koerkamp, Bas Groot ;

Bruix, Jordi ;

Forner, Alejandro ;

Bridgewater, John ;

Valle, Juan W. ;

Gores, Gregory J. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (09) :557-588

[7] High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study [J].

Bi, Chao ;

Liu, Mei ;

Rong, Weiqi ;

Wu, Fan ;

Zhang, Yang ;

Lin, Shengtao ;

Liu, Yunhe ;

Wu, Jianxiong ;

Wang, Liming .

BMC CANCER, 2019, 19 (1)

[8] Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients [J].

Cao, Jingyu ;

Hu, Jing ;

Liu, Siqin ;

Meric-Bernstam, Funda ;

Abdel-Wahab, Reham ;

Xu, Junjie ;

Li, Qiang ;

Yan, Maolin ;

Feng, Yujie ;

Lin, Jianzhen ;

Zhao, Songhui ;

Wang, Jian ;

Kwong, Lawrence N. ;

Hu, Jinwei ;

Carapeto, Fernando ;

Borad, Mitesh J. ;

Wang, Kai ;

Javle, Milind ;

Zhao, Haitao .

JCO PRECISION ONCOLOGY, 2020, 4 :557-569

[9] FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation [J].

Casak, Sandra J. ;

Pradhan, Shan ;

Fashoyin-Aje, Lola A. ;

Ren, Yi ;

Shen, Yuan-Li ;

Xu, Yuan ;

Chow, Edwin Chiu Yuen ;

Xiong, Ye ;

Zirklelbach, Jeanne Fourie ;

Liu, Jiang ;

Charlab, Rosane ;

Pierce, William F. ;

Fesenko, Nataliya ;

Beaver, Julia A. ;

Pazdur, Richard ;

Kluetz, Paul G. ;

Lemery, Steven J. .

CLINICAL CANCER RESEARCH, 2022, 28 (13) :2733-2737

[10] FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? [J].

Chmiel, Paulina ;

Geca, Katarzyna ;

Rawicz-Pruszynski, Karol ;

Polkowski, Wojciech P. ;

Skorzewska, Magdalena .

CELLS, 2022, 11 (23)

← 1 2 3 4 5 6 7 8 9 →